Neovasc Inc., An Opko Health, Inc. Investee, Receives FDA Conditional Approval To Initiate TIARA-I Trial In U.S.: A Multinational, Multicenter Early Feasibility Trial Of The Tiaratm Transcatheter Mitral Valve

MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) announced that its investee, Neovasc, has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the U.S. arm of its TIARA-I Early Feasibility Trial for the Company’s Tiara™ transcatheter mitral valve. The TIARA-I Early Feasibility Trial is a multinational, multicenter trial being conducted to assess the safety and performance of Neovasc’s Tiara mitral valve system and implantation procedure in high-risk surgical patients suffering from severe mitral regurgitation (MR).

Severe MR is a critical condition that affects millions of patients and, if left untreated, can lead to heart failure or death. This FDA conditional approval allows clinical investigators to begin enrolling patients at participating U.S. medical centers once local hospital and related approvals are in place.

Help employers find you! Check out all the jobs and post your resume.